Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1966 2
1967 1
1968 1
1969 2
1970 2
1977 2
1978 2
1979 5
1980 1
1981 2
1985 1
1987 4
1988 3
1989 11
1990 8
1991 12
1992 11
1993 9
1994 6
1995 6
1996 9
1997 10
1998 13
1999 14
2000 19
2001 27
2002 19
2003 22
2004 12
2005 28
2006 25
2007 13
2008 18
2009 13
2010 14
2011 12
2012 16
2013 14
2014 14
2015 15
2016 18
2017 10
2018 13
2019 15
2020 20
2021 15
2022 15
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Raghu G, et al. Among authors: azuma a. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. Am J Respir Crit Care Med. 2018. PMID: 30168753
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. Among authors: azuma a. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. Among authors: azuma a. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Richeldi L, et al. Among authors: azuma a. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569036 Clinical Trial.
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, Hudson M, Kaner RJ, Kolb M, Scholand MB, Steen V, Thomson CC, Volkmann ER, Wigley FM, Burlile D, Kemper KA, Knight SL, Ghazipura M. Raghu G, et al. Among authors: azuma a. Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152. doi: 10.1164/rccm.202306-1113ST. Am J Respir Crit Care Med. 2024. PMID: 37772985 Free PMC article.
Pirfenidone in idiopathic pulmonary fibrosis.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Among authors: azuma a. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8. Eur Respir J. 2010. PMID: 19996196 Free article. Clinical Trial.
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Highland KB, et al. Among authors: azuma a. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1. Lancet Respir Med. 2021. PMID: 33412120 Free article. Clinical Trial.
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Gordat M, Liu Y, Stowasser S, Zoz DF, Wijsenbeek MS. Richeldi L, et al. Among authors: azuma a. BMJ Open Respir Res. 2023 Aug;10(1):e001563. doi: 10.1136/bmjresp-2022-001563. BMJ Open Respir Res. 2023. PMID: 37597969 Free PMC article. Clinical Trial.
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators. Allanore Y, et al. Among authors: azuma a. Ann Rheum Dis. 2022 Dec;81(12):1722-1729. doi: 10.1136/ard-2022-222564. Epub 2022 Aug 16. Ann Rheum Dis. 2022. PMID: 35973804 Free PMC article.
511 results